167 related articles for article (PubMed ID: 14569947)
21. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy.
Tsavaris N; Kosmas C; Mylonakis N; Bacoyiannis C; Kalergis G; Vadiaka M; Boulamatsis D; Iakovidis V; Kosmidis P
Anticancer Res; 2000; 20(6C):4777-83. PubMed ID: 11205218
[TBL] [Abstract][Full Text] [Related]
22. [The 5HT3-receptor antagonist Zofran (ondansetron) as an agent for preventing nausea and vomiting during the cytostatic treatment of cancer patients].
Perevodchikova NI; Volkova MA; Gorbunova VA; Manziuk LV; Marenich AF; Smirnova NB
Ter Arkh; 1996; 68(2):30-4. PubMed ID: 8771653
[TBL] [Abstract][Full Text] [Related]
23. Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin.
Advani SH; Gopal R; Dhar AK; Lal HM; Cooverji ND
J Assoc Physicians India; 1996 Feb; 44(2):127-30. PubMed ID: 10999066
[TBL] [Abstract][Full Text] [Related]
24. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
25. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract][Full Text] [Related]
26. [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy].
Zhou J; Xu B; Zhou A
Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):460-2. PubMed ID: 10920884
[TBL] [Abstract][Full Text] [Related]
27. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy.
Legha SS; Hodges C; Ring S
Cancer; 1992 Oct; 70(7):2018-20. PubMed ID: 1388090
[TBL] [Abstract][Full Text] [Related]
29. [Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Takenaka M; Okamoto Y; Ikeda K; Hashimoto R; Ueda T; Kurokawa N; Takagi T; Uejima E
Gan To Kagaku Ryoho; 2007 Mar; 34(3):403-7. PubMed ID: 17353632
[TBL] [Abstract][Full Text] [Related]
30. Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients.
Rigacci L; Landi C; Caruso JP; Puccini B; Alterini R; Carrai V; Perrone T; Bosi A
Leuk Res; 2012 Feb; 36(2):182-5. PubMed ID: 21752467
[TBL] [Abstract][Full Text] [Related]
31. Acute and delayed nausea and emesis control in pediatric oncology patients.
Holdsworth MT; Raisch DW; Frost J
Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
[TBL] [Abstract][Full Text] [Related]
32. [Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
Miyashita M; Onda M; Ikeda K; Bando K; Hagiwara N; Tsuchiya Y; Yoshiyuki T; Kiyama T; Saito T; Sasajima K; Yamashita K
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1629-35. PubMed ID: 10553422
[TBL] [Abstract][Full Text] [Related]
33. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
Bosnjak SM; Neskovic-Konstantinovic ZB; Jovanovic-Micic DJ; Mitrovic LB; Radulovic SS
J Chemother; 1996 Aug; 8(4):315-8. PubMed ID: 8873840
[TBL] [Abstract][Full Text] [Related]
34. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
35. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
[TBL] [Abstract][Full Text] [Related]
36. [A randomized trial of Zudan in the prophylaxis of nausea and vomiting induced by cisplatin].
Huang J; Wang Z; Zhou L
Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):153-4. PubMed ID: 10920971
[TBL] [Abstract][Full Text] [Related]
37. Freeze dried ondansetron: first observations with the fast dissolving oral antiemetic Zofran Zydis for the prophylaxis of the cisplatin-induced emesis in gynecological cancer patients.
Lehoczky O; Udvary J; Pulay T
Neoplasma; 2002; 49(2):126-8. PubMed ID: 12088106
[TBL] [Abstract][Full Text] [Related]
38. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.
Beck TM; York M; Chang A; Navari R; Harvey WH; Meshad M; Griffin D; Wentz A
Cancer Invest; 1997; 15(4):297-303. PubMed ID: 9246149
[TBL] [Abstract][Full Text] [Related]
39. [Nausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugs].
Zhang P; Feng F; He Y; Li Y; Zhou M; Cheng G; Chen Y
Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):504-7. PubMed ID: 12485511
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin.
Pectasides D; Dafni U; Aravantinos G; Timotheadou E; Skarlos DV; Pavlidis N; Gaglia A; Kalofonos HP; Fountzilas G
Anticancer Res; 2007; 27(6C):4411-7. PubMed ID: 18214053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
